AstraZeneca announced a $2 billion investment to expand biologics manufacturing in Maryland, enlarging its Frederick biologics plant and building a new clinical production site in Gaithersburg. The company said the plan will nearly double commercial biologics capacity, bring parts of its rare-disease portfolio onshore for the first time, and create or support 2,600 jobs across both sites. AstraZeneca intends the facilities to leverage AI, automation and data analytics and to meet high environmental standards, with operations targeted for 2029. The move reinforces onshoring of critical biologics capacity and expands U.S. supply resilience for large-molecule medicines.